A Study of a New PET Scanner in People With Cancer
Recruiting · NCT07690917 · Observational (researchers observe without assigning treatment) · Lead sponsor: Memorial Sloan Kettering Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
Biograph Vision Quadra scannerPET/CT
What this trial is about
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Eligibility Criteria for objective #1:
- Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
- Patients who are undergoing a planned PET-CT scan at main campus of MSK.
- Patients must be ≥ 18 years old
- Eligibility Criteria for objective #2:
- Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
- Patients with metastatic prostate or head and neck cancer.
- Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
- Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
- Patients must be ≥ 18 years old
- Eligibility Criteria for objective #3:
- Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
- Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
- Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
- Patients must be ≥ 18 years old
Exclusion criteria
- Patients who suffer from claustrophobia.
- Women who are pregnant or breast-feeding.
- Patients \< 18 years of age
Where it is running
14 locations listed across 2 US states.
- Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Consent Only ) - Montvale, New Jersey, United States
- Memorial Sloan Kettering Bergen (Consent Only ) - Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) - Commack, New York, United States
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) - Commack, New York, United States
- Memorial Sloan Kettering Westchester (Consent Only) - Harrison, New York, United States
- Memorial Sloan Kettering Westchester (Consent Only) - Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center - New York, New York, United States
- Memorial Sloan Kettering Cancer Center - New York, New York, United States
- Memorial Sloan Kettering Nassau (Consent Only) - Rockville Centre, New York, United States
- Memorial Sloan Kettering Nassau (Consent Only) - Rockville Centre, New York, United States